Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01602666 · ClinicalTrials.gov registry record · Phase 2

Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

A Phase 2 study of Central Nervous System Nongerminomatous Germ Cell Tumor and Childhood Germinoma, sponsored by Children's Oncology Group.

Completed
Registry status
Phase 2
Development phase
262
Enrollment target
20
Study locations

NCT01602666 is a Phase 2 study of Central Nervous System Nongerminomatous Germ Cell Tumor and Childhood Germinoma that has completed, run by Children's Oncology Group. The registered enrollment target is 262 participants. The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01602666, a Phase 2 study of Central Nervous System Nongerminomatous Germ Cell Tumor and Childhood Germinoma, has completed, sponsored by Children's Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase
262 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial studies how well chemotherapy followed by radiation therapy work in treating younger patients with newly diagnosed central nervous system germ cell tumors that have not spread to other parts of the brain, spinal canal, or body (localized). Drugs used as chemotherapy, such as carboplatin, etoposide, and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x rays to kill tumor cells. Giving chemotherapy followed by radiation therapy may kill more tumor cells.

Interventions

  • RADIATION 3-Dimensional Conformal Radiation Therapy
  • DRUG Carboplatin
  • DRUG Etoposide
  • DRUG Ifosfamide
  • RADIATION Intensity-Modulated Radiation Therapy

Study Locations (20)

California

  • Kaiser Permanente Downey Medical Center - Downey
  • Miller Children's and Women's Hospital Long Beach - Long Beach
  • Children's Hospital Los Angeles - Los Angeles
  • Cedars Sinai Medical Center - Los Angeles
  • Mattel Children's Hospital UCLA - Los Angeles
  • Valley Children's Hospital - Madera
  • UCSF Benioff Children's Hospital Oakland - Oakland
  • Kaiser Permanente-Oakland - Oakland
  • Children's Hospital of Orange County - Orange
  • Lucile Packard Children's Hospital Stanford University - Palo Alto
  • Sutter Medical Center Sacramento - Sacramento
  • Rady Children's Hospital - San Diego - San Diego
  • UCSF Medical Center-Parnassus - San Francisco
  • UCSF Medical Center-Mission Bay - San Francisco
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center - Torrance

Alabama

  • Children's Hospital of Alabama - Birmingham
  • University of Alabama at Birmingham Cancer Center - Birmingham

Arizona

  • Phoenix Childrens Hospital - Phoenix

Colorado

  • Children's Hospital Colorado - Aurora

Connecticut

  • Connecticut Children's Medical Center - Hartford

Trial Details

FieldValue
Enrollment Target 262 participants
Start Date 2012-06-27
Est. Completion 2024-09-30
Phase Phase 2

Sponsor

Children's Oncology Group

342 total trials

What the Registry Record Tells You About NCT01602666

The ClinicalTrials.gov registry entry for NCT01602666 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 262 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Central Nervous System Nongerminomatous Germ Cell Tumor appearing as the primary indexed condition, and to 5 interventions - of which 3-Dimensional Conformal Radiation Therapy is the first listed.

NCT01602666 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT01602666 about?

NCT01602666 is a clinical study titled "Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors". This phase II trial studies how well chemotherapy followed by radiation therapy work in treating younger patients with newly diagnosed central nervous system germ cell tumors that have not spread to other parts of the brain, spinal canal, or body (localized). Drugs used as chemotherapy, such as carb...

What is the current status of trial NCT01602666?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 262 participants. The study started on 2012-06-27. Estimated completion is 2024-09-30.

What conditions does trial NCT01602666 study?

This clinical trial studies the following conditions: Central Nervous System Nongerminomatous Germ Cell Tumor, Childhood Germinoma.

What interventions are being tested in trial NCT01602666?

The interventions under investigation include: 3-Dimensional Conformal Radiation Therapy (RADIATION), Carboplatin (DRUG), Etoposide (DRUG), Ifosfamide (DRUG), Intensity-Modulated Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT01602666?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01602666 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Central Nervous System Nongerminomatous Germ Cell Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.